全球要聞:Nation sees therapeutics success
DomesticallydevelopedCOVID-19drugtherapieslowerriskofhospitalization
Chinawillcreatebroad-spectrumtreatmentstotacklemutatedstrainsoftheCOVID-19virusanddevelopdrugswithnovelmechanismstofightthepathogen,accordingtoadocumentprovidedtoChinaDaily.
(相關資料圖)
AsofJan19,atotalof10domesticallymadeCOVID-19drugshadeitherbeengrantedofficialorconditionalmarketapprovalorwereauthorizedtotreatsymptomsofthepathogen,thedocumentstated.
ThedocumentwasissuedbythespecializedteamforCOVID-19medicineresearchanddevelopmentundertheJointPreventionandControlMechanismoftheStateCouncil,China"sCabinet.
Chinaalsohad23drugsonthekeyCOVID-19medicinelistthatwereinactivedevelopmentorundergoingreal-worldevidencestudiesafterreceivingmarketapproval,itsaid.
"Theteamwillcontinuetofacilitatethedevelopmentofsafeandeffectivetreatmentsthatcancoverthewholecourseofthediseaseandaresuitableforallpopulations,"itadded.
SincetheCOVID-19pandemicbegan,China"snovelcoronavirusdrugdevelopmentprocesshasfollowedthreebroadtechnicalpaths-stoppingthevirusfromenteringcells,inhibitingviralreplicationinthebodyandregulatingthebody"simmunesystem.
InDecember2021,Chinagrantedofficialmarketapprovaltoitsfirsthomegrownneutralizingmonoclonalneutralizingantibodycocktails-BRII-196andBRII-198.Itisacombinationtherapyadministeredthroughintravenousinfusionthatcanlowertheriskofhospitalizationanddeathbynearly80percent,accordingtoitsphase-threeclinicaltrialresults.
Meanwhile,Chinesescientistshavebeendevelopingsmall-moleculeoraltreatmentsforCOVID-19.AbreakthroughcameinJulywhenChinagrantedconditionalauthorizationfortheoralantiviralAzvudinetotreatCOVID-19.ThedrugwasoriginallyusedtotreatHIV.
Thisyear,Chinawillacceleratethedevelopmentofsmall-moleculeoraldrugs.Inmid-January,theNationalMedicalProductsAdministrationreceivedapplicationsformarketapprovalfornewantiviralsSIM0417andVV116.AnotherantiviralcalledRAY1216hadrecentlyfinishedrecruitingforitslate-stageclinicaltrials.
BesidesfindingtreatmentsforCOVID-19,Chinesescientistsareresearchingnewdrugstopreventinfectionsorregulatethebody"simmunesystem,withahandfulofcandidatescurrentlyinphasetwoorthreeclinicaltrials.SomenotableexamplesincludethetargetedinhibitordrugTDI01andHY3000peptidenasalspray.
zhangzhihao@chinadaily.com.cn
- 1 蘋果開始研發20寸折疊屏 折疊狀態下為15.3英寸
- 2 手機電池保養小技巧 先來看看你有沒有這樣的習慣
- 3 小米13創新搭載科技納米皮背殼 更耐臟還不變色
- 4 平臺2023年元旦假期機票搜索量漲超5倍 這次假期不需要調休
- 5 2023年旅行搜索量同比上漲超900% 大家明年有什么計劃嗎?
- 6 iQOO 11系列正式亮相 批搭載高通第二代驍龍8移動平臺
- 7 AMD最火處理器正悄悄漲價 當前渠道最熱銷的CPU處理器是哪款?
- 8 智能手表銷量繼續增長 蘋果在智能手表品類市場份額上漲至20%
- 9 國內快遞業務量再創新高 快遞業務量提前7天完成超千億件指標
- 10 耳機也要付費解鎖功能了 這些附加功能確實可以按需訂閱